Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
Robert G MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Type 2 diabetes is a progressive disease associated with high levels of morbidity and mortality and for which there is both a large and growing prevalence worldwi...
Guardado en:
Autor principal: | Moses R |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f258fc99a07a408ba0b23c9f089a972e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
por: Xie J, et al.
Publicado: (2019) -
Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
por: Robert G Moses
Publicado: (2010) -
Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker CM, et al.
Publicado: (2016) -
Fixed combination of repaglinide and metformin in the management of type 2 diabetes
por: Robert Moses
Publicado: (2009) -
Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
por: Schwartz SS, et al.
Publicado: (2016)